CD19 and acute myeloid leukemia: However, the CAR-T concept frequently targets ubiquitously expressed antigens like CD19 for B cell malignancies [5], or FLT-3 [6] for acute myeloid leukemia (AML), as well as stress antigens like NKG2D (natural-killer group 2, member D) for a broader range of cancers [7], raising the question of whether such strategies result as collateral damage in either the long-term deletion of essential hematopoietic subsets or within the context of physiological or therapeutic stress like irradiation to self-reactivity.